Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger RNA (mRNA). The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. The Company develops technologies that enable the development of mRNA medicines for diverse applications. The Company has created modalities, including Prophylactic vaccines, Systemic secreted and cell surface therapeutics, Cancer vaccines, Intratumoral immuno-oncology, Localized regenerative therapeutics, and Systemic intracellular therapeutics. Its diverse development pipeline which consists of 27 development candidates across its 24 programs.
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. It develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Here they are, sorted by how much the stocks have returned this year through Nov. 18:
|COMPANY||TOTAL RETURN — 2020 THROUGH NOV. 19|
|SunRun Inc. RUN, -1.79%||311%|
|Etsy Inc. ETSY, +10.65%||187%|
|Penn National Gaming Inc. PENN, +1.25%||163%|
|Boston Beer Co. Class A SAM, -0.19%||143%|
|Nvidia Corp. NVDA, +0.20%||129%|
|Green Dot Corp. Class A GDOT, -1.65%||124%|
|Generac Holdings Inc. GNRC, +2.25%||111%|
Under the terms of the definitive merger agreement, which was unanimously approved by the Boards of Directors of both companies, CIT stockholders will receive 0.0620 shares of First Citizens class A common stock for each share of CIT common stock they own. First Citizens stockholders will own approximately 61% and CIT stockholders will own approximately 39% of the combined company.
The combined company will operate under the First Citizens name and will trade under the First Citizens ticker symbol FCNCA on the Nasdaq stock market. The combined company will be headquartered in Raleigh, N.C., and will maintain significant operation centers in New York, Pasadena, Omaha, Phoenix, Jacksonville, Fla., New Jersey and Columbia, S.C., among other locations.
Right Answer ~ Wrong Question
If you’re wondering what ultra-low or even negative interest rates will do to the financial markets, you are not alone. Warren Buffett is wondering too.
When I asked Warren Buffett specifically what are the actual implications of negative rates, he went positively Yoda on me. “I would say that’s the most important question in the world,” said the Oracle of Omaha. “And I don’t know the answer. Now, if we knew the answer, it wouldn’t be the most important question.”